How Aflibercept Works
Diabetic macular edema develops when high blood sugar damages the tiny blood vessels in your retina, causing them to leak fluid into the macula. The macula is the part of your retina responsible for sharp, detailed central vision. When fluid accumulates there, your vision becomes blurry, distorted, or dim. Aflibercept works by blocking a protein called vascular endothelial growth factor (VEGF), which is one of the main signals that tells damaged blood vessels to leak.
Aflibercept acts as a decoy receptor, trapping VEGF molecules before they can attach to the blood vessel walls and trigger leakage. It binds to multiple forms of VEGF, including VEGF-A, VEGF-B, and another growth factor called placental growth factor (PlGF). This broader binding profile may provide more complete suppression of the signals driving leakage compared to treatments that target only one form of VEGF. The result is less fluid leaking into the macula and, over time, a drier, healthier retina with improved vision. Its relatively small molecular size also allows it to penetrate effectively into the retinal tissue, reaching the areas where it is needed most.
Aflibercept is delivered through an intravitreal injection, which means it is injected directly into the vitreous gel inside your eye. The procedure is performed in your eye doctor's office and takes only a few minutes. Before the injection, your doctor numbs the surface of your eye with anesthetic drops and cleans the area around your eye with an antiseptic solution to minimize the risk of infection.
A very fine needle is used to deliver a tiny volume of medication through the white part of the eye. Most patients feel pressure rather than sharp pain. After the injection, you may notice temporary floaters, mild redness at the injection site, or a scratchy feeling that resolves within a day or two. Your doctor will check your eye before you leave and give you instructions for any follow-up care. You can typically return to your normal activities the same day.
Eye drops cannot deliver enough medication to the retina because the drug would have to pass through multiple layers of tissue and would be diluted far too much along the way. Oral medications face a similar challenge: the blood-retina barrier prevents most drugs in the bloodstream from reaching the inside of the eye in sufficient concentrations. Injecting the medication directly into the vitreous cavity places it right next to the retina, where it can act quickly and at a therapeutic concentration.
While the idea of an eye injection can feel intimidating, the procedure has become one of the most commonly performed treatments in eye care. Millions of intravitreal injections are given worldwide each year, and the safety record is strong. Your eye doctor has extensive training and experience with this procedure and will take every precaution to make the experience as comfortable as possible for you.
Treatment Schedule and What to Expect
Treatment with aflibercept typically begins with a loading phase of monthly injections. For the standard formulation, the usual loading schedule is one injection every four weeks for the first five doses. This initial series of injections builds up the concentration of the drug in your eye and gives the medication time to dry out the macula and stabilize the retina. Your eye doctor will monitor your progress with optical coherence tomography (OCT) scans at each visit to see how the swelling is responding.
Sticking to the loading phase schedule is important for achieving the best possible outcome. Missing doses or spacing them too far apart during this critical early period can allow fluid to re-accumulate and may reduce the overall benefit of treatment. If scheduling is a challenge, talk to your eye doctor's office about finding appointment times that work for you.
After the loading phase, your eye doctor will begin extending the time between injections based on how your eye is responding. The standard formulation is typically given every eight weeks during the maintenance phase. A higher-dose formulation has been approved that may allow even longer intervals between injections, potentially extending to every eight to twelve weeks for some patients after the initial loading phase.
Many doctors use a treat-and-extend approach, where the interval between injections is gradually lengthened as long as the macula remains dry and stable. If fluid returns, the interval is shortened back. This personalized approach ensures you receive enough treatment to keep the disease controlled while minimizing the number of injections and office visits over time. Research has shown that the treat-and-extend method achieves outcomes comparable to fixed monthly dosing while requiring fewer total injections.
Diabetic macular edema is a chronic condition, and most patients need ongoing treatment to keep the fluid under control. Some patients achieve long-term stability and can eventually stop injections or move to very infrequent monitoring, but others need continued treatment for years. Your eye doctor will assess your individual response and adjust your treatment plan accordingly.
It is important to continue follow-up visits even if your vision feels stable. Fluid can return without causing noticeable symptoms at first, and catching a recurrence early means it can be treated before vision is affected. Your eye doctor uses OCT scans to detect subtle changes in retinal thickness that you would not notice on your own. Stopping treatment or skipping follow-up appointments without your eye doctor's guidance can lead to a setback that is harder to reverse. Maintaining a consistent treatment relationship with your eye doctor gives you the best long-term outcome.
Clinical Evidence Supporting Aflibercept
Aflibercept was evaluated in two large, parallel clinical trials called VIVID and VISTA, which compared the medication to laser treatment for diabetic macular edema. These studies enrolled patients from multiple centers worldwide and followed them for nearly three years. Patients who received aflibercept injections showed significantly better visual improvement compared to those treated with laser at every time point measured, including at one year, two years, and nearly three years of follow-up.
The results were clear: intravitreal aflibercept provided superior visual outcomes compared to the previous standard of macular laser treatment. These findings helped establish aflibercept as a first-line treatment for diabetic macular edema and changed the way eye doctors approach this condition. The VIVID and VISTA trials remain foundational evidence supporting the use of this medication.
A major study known as Protocol T, conducted by the Diabetic Retinopathy Clinical Research Network, compared aflibercept directly against two other anti-VEGF medications in patients with diabetic macular edema. The study found that all three medications improved vision, but aflibercept showed a particular advantage in patients who started with worse baseline vision. In those patients, aflibercept produced significantly better visual gains at one year compared to the other treatments studied.
For patients who started with relatively good vision, the differences between the medications were smaller. This finding suggests that aflibercept may be an especially strong choice when diabetic macular edema has already caused notable vision loss. Your eye doctor considers these study results along with your individual circumstances when recommending a treatment plan.
A higher-dose formulation of aflibercept has been developed and approved for use in diabetic macular edema. This formulation delivers a larger amount of the drug per injection, which may provide longer-lasting suppression of VEGF and allow for extended intervals between treatments. Clinical trials of the higher-dose formulation showed that many patients could maintain their visual gains with injections given every twelve weeks after the initial loading period, compared to every eight weeks with the standard dose.
Fewer injections mean fewer office visits, less time spent in the treatment chair, and less cumulative exposure to the injection procedure. For patients who find the frequency of standard dosing burdensome, the higher-dose option may provide a meaningful improvement in quality of life while maintaining the same level of disease control. Your eye doctor can discuss whether the higher-dose formulation is appropriate for your situation.
Safety and Side Effects
The most common side effects of aflibercept injections are related to the injection procedure itself rather than the medication. These include mild eye irritation, a small area of redness on the white of the eye where the needle entered (subconjunctival hemorrhage), temporary blurry vision immediately after the injection, and the sensation of something in the eye. These effects are usually mild and resolve on their own within a few days.
Some patients experience temporary floaters, which are small spots or strands drifting across their field of vision. These are caused by tiny air bubbles or particles of the medication in the vitreous gel and typically disappear within hours to days. Eyelid swelling can also occur but is usually minor and short-lived. If any side effect persists or worsens, contact your eye doctor's office for guidance.
Serious complications from aflibercept injections are uncommon. Endophthalmitis, an infection inside the eye, is the most serious potential risk and occurs in a very small fraction of injections. Symptoms of endophthalmitis include increasing pain, worsening redness, and rapidly declining vision in the days following an injection. If you experience any of these symptoms, contact your eye doctor immediately, as early treatment is critical.
Other rare risks include retinal detachment, elevated eye pressure, and damage to the lens during the injection procedure. These complications are observed in a very small percentage of cases. Your eye doctor follows strict sterile technique during every injection to minimize risk, and the overall safety profile of intravitreal aflibercept is well established through years of clinical experience and millions of administered doses worldwide.
Aflibercept should not be used in patients who have an active infection in or around the eye, active inflammation inside the eye, or a known allergy to aflibercept or any of its ingredients. Your eye doctor will review your medical history before starting treatment to ensure the medication is safe for you. If you have recently had eye surgery or have elevated eye pressure, your doctor may delay treatment until these issues are resolved.
Let your eye doctor know about all of your medical conditions, including any history of blood clots or stroke, as these may be relevant to your treatment plan. Your doctor will weigh the benefits of treatment against any individual risk factors and discuss the plan with you so you can make an informed decision.
How Aflibercept Compares to Other Treatment Options
Several anti-VEGF medications are available for treating diabetic macular edema, and all work by blocking VEGF to reduce leakage. Aflibercept differs from some other options in that it binds to a broader range of growth factors, including VEGF-B and placental growth factor, in addition to VEGF-A. Laboratory studies show that aflibercept has a higher binding affinity for VEGF compared to some other available agents, which may contribute to its effectiveness.
Clinical studies have shown that all approved anti-VEGF medications are effective for DME, with differences emerging primarily in patients with more severe vision loss at baseline. Your eye doctor selects the medication based on your individual response, the severity of your disease, your treatment history, and practical factors such as dosing intervals and availability. Some patients respond better to one medication than another, and switching is an option if the first choice does not produce adequate results.
Steroid implants are another treatment option for diabetic macular edema. These implants are placed inside the eye and release anti-inflammatory medication slowly over months. Steroids work through a different mechanism than anti-VEGF agents, targeting inflammation rather than VEGF directly. They may be considered for patients who do not respond adequately to anti-VEGF injections or who have difficulty maintaining a frequent injection schedule.
However, steroid implants carry a higher risk of elevating eye pressure and accelerating cataract formation compared to anti-VEGF medications. For most patients with DME, anti-VEGF therapy such as aflibercept is recommended as the first-line treatment because of its favorable balance of effectiveness and safety. Your eye doctor will discuss steroid options if your disease does not respond sufficiently to anti-VEGF therapy alone.
Laser treatment for diabetic macular edema was the standard of care before anti-VEGF medications became available. While laser can still play a role in some cases, clinical trials have clearly demonstrated that aflibercept produces better visual outcomes than laser for most patients with center-involving DME. Aflibercept not only improves vision more than laser but also carries a lower risk of the permanent retinal scarring that laser can sometimes cause.
Some patients may still receive laser treatment as a supplemental therapy alongside anti-VEGF injections, particularly if their macular edema has a focal leaking pattern that can be targeted with laser. However, for the majority of patients with diabetic macular edema affecting the center of their vision, anti-VEGF therapy is the preferred first-line approach. Your eye doctor will determine the best combination of treatments for your specific situation based on the location and pattern of your macular edema, your treatment history, and your overall retinal health.
Common Questions About Aflibercept for Diabetic Macular Edema
Aflibercept binds to multiple forms of the VEGF protein, including VEGF-A, VEGF-B, and placental growth factor. This broader binding profile may provide more complete suppression of the signals driving blood vessel leakage. In clinical trials, aflibercept showed a particular advantage in patients with more severe vision loss at the start of treatment, producing greater visual improvement in that group compared to some other options.
The higher-dose formulation delivers more medication per injection, which may provide longer-lasting VEGF suppression. Clinical trials showed that many patients on the higher dose maintained their visual gains with injections every twelve weeks rather than every eight weeks. This can mean fewer visits and injections over time. Whether the higher dose is right for you depends on your individual response and treatment history, which your eye doctor will evaluate.
The interval between injections depends on how your eye responds to treatment. With the standard formulation, maintenance injections are typically given every eight weeks. The higher-dose formulation may allow intervals of up to twelve weeks for some patients. Using a treat-and-extend approach, your eye doctor gradually lengthens the time between injections as long as your macula stays dry. Some patients eventually extend to several months between treatments.
The most common side effects are mild and related to the injection procedure itself. They include temporary eye redness, minor irritation, brief blurry vision, and floaters. These effects typically resolve within a few days. Serious complications such as eye infection are rare. If you notice increasing pain, worsening redness, or declining vision after an injection, contact your eye doctor right away.
Newer anti-VEGF medications have been developed that offer different dosing schedules or mechanisms of action. Some newer agents target multiple pathways simultaneously or are designed for longer intervals between injections. Clinical trials comparing these medications show that they are generally effective, with differences emerging in specific patient populations or dosing convenience. Your eye doctor stays current with the latest evidence and will recommend the option that best fits your needs.
Yes. Aflibercept has been shown to improve the severity of diabetic retinopathy in addition to treating macular edema. Clinical trials demonstrated that patients receiving aflibercept experienced improvements in their retinopathy severity score, meaning the overall disease in the retina improved, not just the swelling in the macula. This dual benefit makes aflibercept a valuable treatment for patients who have both macular edema and significant underlying retinopathy.